Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
See introductory video with welcome to the ICR
PRIME-ROSE builds on a bottom-up, investigator-initiated family of clinical trials in precision cancer medicine, which have successfully brought up inclusion rates to offer additional lines of treatment and provide patient benefit. At the kick-off in Oslo September 18-20, PRIME-ROSE partners and key stakeholders met to go through the work plan and accelerate the start-up of the project tasks.
PRIME-ROSE Coordinator Kjetil Taskén says: “Most importantly, PRIME-ROSE will allow us to search around Europe to find patients with rare combinations of cancer disease, biomarker, and treatment in parallel ongoing trials to build the evidence of what treatments are working for patients. This is a “triple-win” – for patients, investigators and industry partners – as we will build the knowledge base faster and more effectively”.
Professor Johanna Olweus, leader of the Experimental Immunotherapy Group at the Department of Cancer Immunology, has been selected for the final of the Cancer Grand Challenges as part of a global research team. If successful, the team hopes to contribute in giving cancer patients new therapies.
"Reaching the final in competition with top research teams from all over the world is incredibly exciting and a great recognition of the work of my group," says Johanna Olweus.
Dr. Özlem Türeci, Chief Medical Officer, BioNTech and Professor, Mainz University Medical Ctr & Helmholtz Institute for Translational Oncology visits Radiumhospitalet/OCC on November 16th to give a lecture.
Time and place: – , Radiumhospitalet/OCC, Kaare Norum Auditorium
NB: Registration necessary
Dr. Tureci will also give a talk at 1800 the same day in the Norwegian Academy of Science and Letters with title: “Vaccines: mRNA vaccine technology - COVID-19, Cancer & beyond”.
OUS-CCC (Comprehensive Cancer Centre) is involved in the major EU grant CCI4EU - aimed at improving cancer infrastructures in Europe through developing or improving Comprehensive Cancer Infrastructures. The project involves 55 partners and has a duration of 36 months. Work Package 4 (WP4) is "Development of personalised capacity building (CB) tailored interventions" where OUS-CCC is co-lead together with Vall d´Hebron Hospital.
OUS-CCC initiated the WP4 participation with a visit to partner and co-lead Claudia Valverde at Vall d’Hebron Hospital, Barcelona. The entourage consisted of head of OUS-CCC Sigbjørn Smeland, Ingrid Jenny Guldvik, Anders Øverbye and Per Magnus Mæhle.
Information from UiO Growth House:
Spend a day with great science, innovation and networking opportunities at this meeting place for academia, the institute sector, the public sector, start-ups and industry. The innovation conference has sessions on life sciences and energy & environment and is a part of Oslo Innovation Week 2023.
Time and place: Sep. 27, 2023 8:00 AM – 8:00 PM, Oslo Science Park, Gaustadalléen 21, Oslo
Read more about the innovation conference and sign up! (www.uio.no)
The Centre for Molecular Medicine Norway (NCMM) is pleased to announce the opening of the NCMM Joint Postdoctoral Program in Molecular Life Science, aimed at fostering new collaborations between NCMM group leaders (GLs) and partners from the Oslo arena. This program provides a unique opportunity for researchers to engage in joint supervision and mentorship of talented postdoctoral researchers, with the goal of advancing the frontiers of molecular life science through interdisciplinary collaborations.
Application Deadline: October 31st, 2023